Navigation Links
China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006
Date:12/19/2007

HARBIN, China, Dec. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (OTC Bullion Board: CSKI), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that it has filed the previously announced amendments to the Company's Form 10QSB for the fiscal quarters ended June 30, 2006 and September 30, 2006. The Company filed its full year 2006 amendments on November 8, 2006. Today's amendments complete the Company's obligation to amend its numbers for the fiscal year 2006 and do not impact financial results reported in the year 2007.

On November 8, 2007, the Company explained that net income for the year 2006 was adjusted to account for $3.67 million of costs that were incorrectly treated, including roughly $1.8 million of one-time costs related to the Company's 2006 recapitalization, as well as approximately $1.8 million of capitalized research and development costs which should have been charged to operations when incurred. As such, full year 2006 net income was adjusted to $630,000 from $4.3 million.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company's principal revenue source is the manufacture and sale of over-the-counter pharmaceutical products.

http://www.skyonemedical.com

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

In the United States:

Ashley Ammon MacFarlane and Bill Zima

Integrated Corporate Relations, Inc.

Tel: +1-203-682-8200 (Investor Relations)

In Asia:

Xuyang Zhang

Integrated Corporate Relations, Inc.

Tel: +86-10-8523-3087 (Investor Relations)


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. ... provides instant absorption from the mouth into the bloodstream. Far outpacing ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new ... now available on the App Store and Google Play . Florida-based ... the addiction and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a ... innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are used ... to accelerate tissue synthesis and provide a faster and more efficient healing process. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five ... of those report that family members or friends have also commented about their ... hearing loss wear hearing aids. One reason, suggested by 89 percent of American ...
(Date:2/22/2017)... North Carolina (PRWEB) , ... February 22, 2017 , ... ... of cats and 54% of dogs, according to the Association for Pet Obesity Prevention ... disagreed on key pet food issues such as the benefits of corn and grains, ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... -- Corin Group announced today the launch of the Humelock ... with both a massive rotator cuff tear and a ... cuff tear arthropathy, causes pain and reduced mobility in ... Reversed Shoulder System, which was developed by FX Solutions, ... Lyon, France , received FDA clearance for ...
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Drug Development Pipeline Review, 2016" report to their offering. ... ... disorders worldwide, and approximately one-third of the US population suffers ... decades, the majority of the dermatology market has remained saturated ...
(Date:2/22/2017)... Research and Markets has announced the addition of ... Small Molecule Drugs), By Route of Administration (Systemic, Topical), By ... report to their offering. ... The global psoriasis drugs market is anticipated ... report provides a detailed analysis of the current and future ...
Breaking Medicine Technology: